{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:25:01Z","timestamp":1793193901138,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10456-021-09807-4","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T06:03:27Z","timestamp":1626933807000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia"],"prefix":"10.1007","volume":"25","author":[{"given":"Joseph G.","family":"Parambil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Gossage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy D.","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. V. Narayanan","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasi L.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P.","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Sprecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"9807_CR1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193003","author":"A Kritharis","year":"2018","unstructured":"Kritharis A, Al-Samkari H, Kuter DJ (2018) Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist\u2019s perspective. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2018.193003","journal-title":"Haematologica"},{"issue":"1","key":"9807_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66\u201367","journal-title":"Am J Med Genet"},{"issue":"3","key":"9807_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccm.2016.04.013","volume":"37","author":"JG Parambil","year":"2016","unstructured":"Parambil JG (2016) Hereditary hemorrhagic telangiectasia. Clin Chest Med 37(3):513\u2013521. https:\/\/doi.org\/10.1016\/j.ccm.2016.04.013","journal-title":"Clin Chest Med"},{"issue":"6","key":"9807_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.blre.2010.07.001","volume":"24","author":"CL Shovlin","year":"2010","unstructured":"Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24(6):203\u2013219. https:\/\/doi.org\/10.1016\/j.blre.2010.07.001","journal-title":"Blood Rev"},{"issue":"21","key":"9807_CR5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/ajmg.a.32243","volume":"146A","author":"TG Letteboer","year":"2008","unstructured":"Letteboer TG, Mager HJ, Snijder RJ, Lindhout D, Ploos van Amstel HK, Zanen P, Westermann KJ (2008) Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A 146A(21):2733\u20132739. https:\/\/doi.org\/10.1002\/ajmg.a.32243","journal-title":"Am J Med Genet A"},{"key":"9807_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24832","author":"RS Kasthuri","year":"2017","unstructured":"Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME, Brain Vascular Malformation Consortium HHTIG (2017) Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.24832","journal-title":"Am J Hematol"},{"issue":"18","key":"9807_CR7","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","volume":"84","author":"JW Donaldson","year":"2015","unstructured":"Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW (2015) Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study. Neurology 84(18):1886\u20131893. https:\/\/doi.org\/10.1212\/WNL.0000000000001538","journal-title":"Neurology"},{"issue":"5","key":"9807_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.otohns.2006.12.019","volume":"136","author":"UW Geisthoff","year":"2007","unstructured":"Geisthoff UW, Heckmann K, D\u2019Amelio R, Grunewald S, Knobber D, Falkai P, Konig J (2007) Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 136(5):726\u2013733. https:\/\/doi.org\/10.1016\/j.otohns.2006.12.019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"9807_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/alr.21374","volume":"4","author":"CA Merlo","year":"2014","unstructured":"Merlo CA, Yin LX, Hoag JB, Mitchell SE, Reh DD (2014) The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol 4(11):921\u2013925. https:\/\/doi.org\/10.1002\/alr.21374","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"9807_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000072411","volume":"110","author":"A Cirulli","year":"2003","unstructured":"Cirulli A, Liso A, D\u2019Ovidio F, Mestice A, Pasculli G, Gallitelli M, Rizzi R, Specchia G, Sabba C (2003) Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 110(1):29\u201332. https:\/\/doi.org\/10.1159\/000072411","journal-title":"Acta Haematol"},{"issue":"6","key":"9807_CR11","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818\u2013828","journal-title":"Haematologica"},{"key":"9807_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008739","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H (2020) Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood. https:\/\/doi.org\/10.1182\/blood.2020008739","journal-title":"Blood"},{"issue":"1","key":"9807_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","volume":"14","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN (2019) Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Orphanet J Rare Dis 14(1):256. https:\/\/doi.org\/10.1186\/s13023-019-1239-6","journal-title":"Orphanet J Rare Dis"},{"key":"9807_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14034","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN (2020) An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia. https:\/\/doi.org\/10.1111\/hae.14034","journal-title":"Haemophilia"},{"key":"9807_CR15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261859","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vazquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN (2020) An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2020.261859","journal-title":"Haematologica"},{"issue":"2","key":"9807_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","volume":"285","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ (2019) Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 285(2):223\u2013231. https:\/\/doi.org\/10.1111\/joim.12832","journal-title":"J Intern Med"},{"issue":"2","key":"9807_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","volume":"93","author":"VN Iyer","year":"2018","unstructured":"Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD, Kamath PS, Misra S, Begna KH, Cartin-Ceba R, DuBrock HM, Krowka MJ, O\u2019Brien EK, Pruthi RK, Schroeder DR, Swanson KL (2018) Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc 93(2):155\u2013166. https:\/\/doi.org\/10.1016\/j.mayocp.2017.11.013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"9807_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Riviere S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948\u2013955. https:\/\/doi.org\/10.1001\/jama.2012.250","journal-title":"JAMA"},{"issue":"1","key":"9807_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","volume":"14","author":"E Buscarini","year":"2019","unstructured":"Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL, Vascern HHT (2019) Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 14(1):28. https:\/\/doi.org\/10.1186\/s13023-018-0982-4","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"9807_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","volume":"77","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Choueiri TK, Sternberg CN (2011) Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77(3):163\u2013171. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.02.012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"9807_CR21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/jth.13683","volume":"15","author":"YH Kim","year":"2017","unstructured":"Kim YH, Kim MJ, Choe SW, Sprecher D, Lee YJ (2017) Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. J Thromb Haemost 15(6):1095\u20131102. https:\/\/doi.org\/10.1111\/jth.13683","journal-title":"J Thromb Haemost"},{"issue":"10","key":"9807_CR22","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/lary.27129","volume":"128","author":"JG Parambil","year":"2018","unstructured":"Parambil JG, Woodard TD, Koc ON (2018) Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 128(10):2234\u20132236. https:\/\/doi.org\/10.1002\/lary.27129","journal-title":"Laryngoscope"},{"issue":"1","key":"9807_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","volume":"22","author":"ME Faughnan","year":"2019","unstructured":"Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CCW, McWilliams JP, Parambil JG, Vozoris N, Donaldson J, Paul G, Berry P, Sprecher DL (2019) Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis 22(1):145\u2013155. https:\/\/doi.org\/10.1007\/s10456-018-9646-1","journal-title":"Angiogenesis"},{"issue":"1","key":"9807_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2010.07.015","volume":"35","author":"RP Gale","year":"2011","unstructured":"Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S (2011) What are RBC-transfusion-dependence and -independence? Leuk Res 35(1):8\u201311. https:\/\/doi.org\/10.1016\/j.leukres.2010.07.015","journal-title":"Leuk Res"},{"issue":"5","key":"9807_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","volume":"25","author":"O Mir","year":"2019","unstructured":"Mir O, Touati N, Lia M, Litiere S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A (2019) Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials. Clin Cancer Res 25(5):1479\u20131485. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2748","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9807_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA (2010) An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 120(4):838\u2013843. https:\/\/doi.org\/10.1002\/lary.20818","journal-title":"Laryngoscope"},{"issue":"5","key":"9807_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/lary.25669","volume":"126","author":"LX Yin","year":"2016","unstructured":"Yin LX, Reh DD, Hoag JB, Mitchell SE, Mathai SC, Robinson GM, Merlo CA (2016) The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope 126(5):1029\u20131032. https:\/\/doi.org\/10.1002\/lary.25669","journal-title":"Laryngoscope"},{"issue":"11","key":"9807_CR28","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","volume":"2","author":"R Invernizzi","year":"2015","unstructured":"Invernizzi R, Quaglia F, Klersy C, Pagella F, Ornati F, Chu F, Matti E, Spinozzi G, Plumitallo S, Grignani P, Olivieri C, Bastia R, Bellistri F, Danesino C, Benazzo M, Balduini CL (2015) Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. The Lancet Haematology 2(11):e465-473. https:\/\/doi.org\/10.1016\/S2352-3026(15)00195-7","journal-title":"The Lancet Haematology"},{"issue":"22","key":"9807_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V128.22.210.210","volume":"128","author":"M Samour","year":"2016","unstructured":"Samour M, Saygin C, Abdallah R, Kundu S, McCrae KR (2016) Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a phase I study. Blood 128(22):210","journal-title":"Blood"},{"key":"9807_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-020-09758-2","author":"S Kroon","year":"2020","unstructured":"Kroon S, Snijder RJ, Hosman AE, Vorselaars VMM, Disch FJM, Post MC, Mager JJ (2020) Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Angiogenesis. https:\/\/doi.org\/10.1007\/s10456-020-09758-2","journal-title":"Angiogenesis"},{"issue":"3","key":"9807_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10456-020-09712-2","volume":"23","author":"DVC de Jel","year":"2020","unstructured":"de Jel DVC, Disch FJM, Kroon S, Mager JJ, Verdam FJ (2020) Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia. Angiogenesis 23(3):271\u2013274. https:\/\/doi.org\/10.1007\/s10456-020-09712-2","journal-title":"Angiogenesis"},{"key":"9807_CR32","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1443","author":"ME Faughnan","year":"2020","unstructured":"Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R (2020) Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. https:\/\/doi.org\/10.7326\/M20-1443","journal-title":"Ann Intern Med"},{"key":"9807_CR33","unstructured":"FDA US Votrient (pazopanib) prescribing information. Novartis"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-021-09807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-021-09807-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-021-09807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:49:07Z","timestamp":1744138147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-021-09807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["9807"],"URL":"https:\/\/doi.org\/10.1007\/s10456-021-09807-4","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Al-Samkari: consultancy (Agios, Dova, Argenx, Rigel, Sobi, Novartis), Research Funding to Institution (Agios, Dova, Amgen). All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Cleveland Clinic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}